Erythropoietin analog-human serum albumin fusion

1. An EPOa-hSA fusion protein, wherein the EPOa moiety is the full coding region of the human EPO sequence but wherein each amino acid residue of the EPOa moiety that serves as a site for glycosylation of the fusion protein is altered such that such a site does not serve as a site for glycosylation glycosylation in the EPOa; and,

wherein both the albumin moiety and the EPOa moiety of the fusion protein is derived from a human sequence.

2. The EPOa.hSA fusion protein of claim 1 , wherein said fusion protein has the formula:

R1-L-R2; R2-L-R1; orR1-L-R2 L-R1, wherein R1 is an erythropoietin og amino acid sequence; L is a peptide linker and R2 is a h serum albumin amino acid sequence.

3. The EPOa-hSA fusion protein of claim 2 , wherein R1 and R2 are covalently linked via said pep de linker.

4. The EPOa-hSA fusion protein of claim 3 , wherein said peptide linker is composed of a sequenc having the formula (Ser-Ser-Ser-Ser-Gly)y (SEQ. ID 5) wherein y is less than or equal to 8.

5. The EPOa.hSA fusion protein of claim 3 , wherein said peptide linker is 10 to 30 amino acids in length.

6. The EPOa-hSA fusion protein of claim 5 , wherein each of said amino acids in said peptide linker is selected from the group consisting of Gly, Ser, Asn, Thr and Ala.

7. The EPOa-hSA fusion protein of claim 5 , wherein said peptide linker is composed of either 2 or tandem repeats of a sequence having the formula ((Ser-Ser-Ser-Ser-Gly) 3 -Ser-Pro (SEQ. ID 4).

8. The EPOa-hSA fusion protein of claim 1 , wherein each amino acid residue which serves as an ent point for glycosylation has been deleted.

9. The EPOa-hSA fusion protein of claim 1 , wherein each amino acid residue of human EPO which serves as a site for glycosylation has been replaced with an amino acid residue which does not serve as a site for glycosylation.

10. The EPOa-hS fusion protein of claim 1 , wherein said amino acid residue is selected from the up consisting of amino acid residues Asn24, Asn38, Asn83 and Ser126.

11. The EPOa-hSA fusion protein of claim 1 , wherein said glycosylation sites altered include Serl2 Asn24, Asn38 and Asn83.

12. The BPOa-hSA fusion protein of claim 1 , wherein saud glycosylation sites altered are either O-linked or N-linked glycosylation sites and are altered by replacing an amino acid residue Am or Ser with a Gln residue.

13. The EPOa-hSA fusion protein of claim 1 , wherein each of the amino acid residues 24, 38, 83 and 126 have been replaced with Gin.

14. The EPOa-hSA fusion protein of claim 1 , wherein each of the amino acid residues 24, 38, 83 and 126 have been deleted.

15. The EPOa-hSA fusion protein of claim 14 , wherein each of the amino acid residues 24, 38 and 83 have been replaced with Gin and wherein said amino acid residue 126 has replaced with Ala.

16. The EPOa-hSA fusion protein of claim 1 , wherein fusion protein includes from left to right, an EPOa which includes amino acid residues Gln24, Gln38, GlnS3 and Ala126, a peptide linker, and hwnan serum albumin.

17. The EPOa-hSA fusion protein of claim 1 , wherein the fusion protein is from left to right, GIn24,iGIn3S, GIn83, Alal26 EPO, apeptide linker having the formula ((Ser-Gly-Gly-Gly-(Gly) 3 -Ser-Pro) (SEQ. ID 4) and human serum albwnin.

18. The EPOa-hSA fusion protein of claim 1 , wherein the EPOa-hSA fusion protein includes, from teft to right, human serum albumin, a peptide linker, and an EPOa which includes amino acid residues Gln24, Gln38, Gln83 and A1a126.

19. The EPOa-hSA fusion protein of claim 18 , wherein the EPOs is Gln24, Gln38, Gln83, Ala126 EPO.

20. The EPOa-hSA fusion protein of claim 1 , wherein the fusion protein is from left to right, human serum albumin, a peptido linker having the formula ((Ser-Gly.Gly-Gly-Gly) 3 -Ser-Pro) (SEQ. ID 4), and Gln24, Gln38, Gln83, Ala 126 EPO.